Proactive Investors - Run By Investors For Investors

ANGLE ground-breaking liquid biopsy to be used in lung cancer study

The Partsortix system will be used in research being carried out by the Hellenic Oncology Research Group
doctors inspecting lung x-ray
Lung cancer has the highest mortality rate of all cancers and there are 2.1mln new cases each year

ANGLE PLC’s (LON:AGL, OTCQX:ANPCY) ground-breaking liquid biopsy system will be incorporated into a clinical study to provide an early warning of relapse among patients being treated for non-small cell lung cancer.

The Partsortix system will be used in research being carried out by the Hellenic Oncology Research Group and will be deployed to track circulating tumour DNA, fragments of dead cancer cells and circulating tumour cells (CTCs).

A total of 50 operable early-stage patients will have blood drawn prior to surgery, one month after the operation and then every three to six months until relapse. 

CTC evaluation is being undertaken by the University of Athens, lead by Professor Evi Lianidou, and the latest collaboration builds on work by the same team using Parsortix in research on head and neck cancer.

 "This is another example of ANGLE's product based leveraged R&D approach delivering key benefits with a major study, which is being developed, executed and funded by a leading customer,” said ANGLE chief executive Andrew Newland. 

“The high incidence and mortality rates of lung cancer create a pressing need for repeat biopsies to allow personalised medicine and we hope that our Parsortix liquid biopsy system can play a key role in delivering this to the benefit of patients, opening new markets for ANGLE."

Shares in ANGLE held steady at 67p in late afternoon trading on Friday.

 -- Adds share price --

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
Cancer cells
February 12 2019
The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise
February 27 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use